CALB2 is a Mechanoresistance Gene in Metastatic Prostate Cancer
Source abstract
Abstract
ABSTRACT It remains unclear how circulating tumor cells (CTCs) adapt to and survive mechanical forces in the bloodstream, including fluid shear stress (FSS), making it critical to define the mechanisms that enable their survival and promote metastasis. To model these forces, we generated “mechanoresistant” (MR) LNCaP and PC3 prostate cancer (PCa) cell lines by repeatedly exposing cells to high‑intensity (HI) FSS (3950 dyn/cm 2 ). LNCaP MR cells acquired marked resistance to HI FSS, exhibiting significantly reduced apoptosis, while PC3 cells demonstrated innate resistance. Bulk RNA‑sequencing revealed that LNCaP and PC3 MR cells developed distinct molecular programs. CALB2 (calretinin) emerged as a mechanoresistance gene selectively upregulated in PC3 MR cells, and CALB2 knockout significantly reduced viability upon re‑exposure to HI FSS. Analysis of CALB2 ‑high PCa cases captured patient‑level molecular heterogeneity, suggesting a mechanoadaptive state rather than a uniform aggressiveness‐driven tumor phenotype. This was consistent with the absence of correlation between CALB2 levels and Gleason Scores. In an orthotopic PCa mouse model, the PC3 MR condition displayed the most aggressive early tumor growth and the largest endpoint tumor volumes, consistent with enhanced proliferation. Together, these findings demonstrate that PCa cells acquire discrete mechanoadaptive phenotypes under extreme FSS, revealing targetable pathways to limit metastatic competence.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Cellular Mechanics and Interactions · Cell Adhesion Molecules Research · Cancer Cells and Metastasis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Biomedical Engineering Vanderbilt University Nashville Tennessee USA
Department of Bioengineering Rice University Houston Texas USA
Funding
Cancer Prevention and Research Institute of Texas
References (96)
Show source-provided references
1. 10.1038/s41416‐022‐02136‐310.1038/s41416‐022‐02136‐3 ↗
2. A. C.Society “What Are the Survival Rates for Prostate Cancer?2024 ” Available at:https://www.cancer.org/cancer/types/prostate‐cancer/detection‐diagnosis‐staging/survival‐rates.html.
3. 10.3389/fonc.2013.0004410.3389/fonc.2013.00044 ↗
4. 10.1038/srep3997510.1038/srep39975 ↗
5. 10.1530/EC‐17‐011810.1530/EC‐17‐0118 ↗
6. 10.3978/j.issn.2223‐4683.2013.09.0310.3978/j.issn.2223‐4683.2013.09.03 ↗
7. 10.1016/j.coche.2016.01.01110.1016/j.coche.2016.01.011 ↗
8. 10.1038/s41419‐019‐2063‐610.1038/s41419‐019‐2063‐6 ↗
9. 10.1371/journal.pone.005097310.1371/journal.pone.0050973 ↗
10. 10.1038/s42003‐024‐06327‐x10.1038/s42003‐024‐06327‐x ↗
11. 10.1242/jcs.25147010.1242/jcs.251470 ↗
12. Fluid Shear Stress and Tumor Metastasis
13. 10.1007/978‐3‐319‐95294‐9_1110.1007/978‐3‐319‐95294‐9_11 ↗
14. 10.3390/ijms2121836110.3390/ijms21218361 ↗
15. 10.1016/j.canlet.2016.12.00110.1016/j.canlet.2016.12.001 ↗
16. 10.1186/s12915‐022‐01266‐710.1186/s12915‐022‐01266‐7 ↗
17. 10.1371/journal.pone.019417010.1371/journal.pone.0194170 ↗
18. 10.1038/srep2707310.1038/srep27073 ↗
19. 10.2147/CHC.S7185210.2147/CHC.S71852 ↗
20. 10.1152/ajpcell.00626.200510.1152/ajpcell.00626.2005 ↗
21. 10.3390/molecules2717543010.3390/molecules27175430 ↗
22. 10.1152/ajpcell.00050.201510.1152/ajpcell.00050.2015 ↗
23. 10.1038/s41416‐024‐02854‐w10.1038/s41416‐024‐02854‐w ↗
24. 10.18632/oncotarget.2633210.18632/oncotarget.26332 ↗
25. Mechanobiology and Survival Strategies of Circulating Tumor Cells: a Process towards the Invasive and Metastatic Phenotype10.3389/fcell.2023.1188499 ↗
26. Fluids and Their Mechanics in Tumour Transit: Shaping Metastasis10.1038/s41568-019-0221-x ↗
27. The LNCaP Cell Line–a New Model for Studies on Human Prostatic Carcinoma
28. LNCaP Model of Human Prostatic Carcinoma
29. 10.1038/s42003‐024‐06327‐x10.1038/s42003‐024‐06327‐x ↗
30. Establishment and Characterization of a Human Prostatic Carcinoma Cell Line (PC‐3)
31. 10.3791/6895710.3791/68957 ↗
32. Modeling the Effects of Hemodynamic Stress on Circulating Tumor Cells Using a Syringe and Needle
33. 10.1136/hrt.53.4.45110.1136/hrt.53.4.451 ↗
34. 10.1002/ijc.2524210.1002/ijc.25242 ↗
35. 10.1371/journal.pone.009625010.1371/journal.pone.0096250 ↗
36. 10.1038/nmeth.201910.1038/nmeth.2019 ↗
37. 10.1007/s10529‐023‐03346‐210.1007/s10529‐023‐03346‐2 ↗
38. 10.1002/cam4.21910.1002/cam4.219 ↗
39. 10.3389/fonc.2015.0015510.3389/fonc.2015.00155 ↗
40. 10.1016/j.tcb.2021.10.00410.1016/j.tcb.2021.10.004 ↗
41. 10.3390/cells903062310.3390/cells9030623 ↗
42. 10.1016/j.devcel.2020.10.01110.1016/j.devcel.2020.10.011 ↗
43. 10.1016/j.bpj.2019.04.01110.1016/j.bpj.2019.04.011 ↗
44. 10.1111/boc.20160007810.1111/boc.201600078 ↗
45. 10.1002/(SICI)1097‐4652(200003)182:3<311::AID‐JCP1>3.0.CO;2‐910.1002/(SICI)1097‐4652(200003)182:3<311::AID‐JCP1>3.0.CO;2‐9 ↗
46. 10.21873/invivo.1240810.21873/invivo.12408 ↗
47. Cell Cycle Analysis Kit. Fluorescent. (ab287852) | Abcam.
48. 10.1073/pnas.071235310510.1073/pnas.0712353105 ↗
49. 10.3892/ijo.2019.483910.3892/ijo.2019.4839 ↗
50. 10.21203/rs.3.rs‐1678497/v110.21203/rs.3.rs‐1678497/v1 ↗
51. 10.1186/s13059‐014‐0550‐810.1186/s13059‐014‐0550‐8 ↗
52. Bioinformatic Analysis of RNA‐Seq Data Unveiled Critical Genes in Rectal Adenocarcinoma
53. 10.1038/ng118010.1038/ng1180 ↗
54. 10.1073/pnas.050658010210.1073/pnas.0506580102 ↗
55. 10.1111/jvh.1226510.1111/jvh.12265 ↗
56. 10.1186/s13148‐022‐01308‐510.1186/s13148‐022‐01308‐5 ↗
57. 10.3892/ol.2018.938110.3892/ol.2018.9381 ↗
58. 10.1016/j.ctrv.2015.05.00110.1016/j.ctrv.2015.05.001 ↗
59. 10.1080/15384047.2023.221604110.1080/15384047.2023.2216041 ↗
60. 10.3389/fnana.2014.0000310.3389/fnana.2014.00003 ↗
61. 10.1016/j.cell.2015.10.02510.1016/j.cell.2015.10.025 ↗
62. 10.1073/pnas.190265111610.1073/pnas.1902651116 ↗
63. 10.1016/j.ccr.2010.05.02610.1016/j.ccr.2010.05.026 ↗
64. 10.3389/fmed.2020.0032010.3389/fmed.2020.00320 ↗
65. 10.1007/s12253‐019‐00787‐x10.1007/s12253‐019‐00787‐x ↗
66. 10.1002/1878‐0261.1274910.1002/1878‐0261.12749 ↗
67. Diagnostic Utility of Calretinin Immunohistochemistry in Cytologic Cell Block Preparations10.1002/1097-0142(20001025)90:5<312::AID-CNCR8>3.0.CO;2-M ↗
68. 10.1016/j.jconrel.2015.12.04810.1016/j.jconrel.2015.12.048 ↗
69. 10.1038/s41598‐024‐59052‐010.1038/s41598‐024‐59052‐0 ↗
70. Generation of Orthotopic Xenograft Mouse Model of Prostate Cancer Validated by 11C‐Choline PET/CT
71. 10.1186/1471‐2121‐9‐410.1186/1471‐2121‐9‐4 ↗
72. 10.1016/j.yexcr.2004.06.00110.1016/j.yexcr.2004.06.001 ↗
73. 10.1038/nature0890810.1038/nature08908 ↗
74. 10.1016/j.bbadis.2024.16733210.1016/j.bbadis.2024.167332 ↗
75. 10.1007/s00109‐012‐0941‐910.1007/s00109‐012‐0941‐9 ↗
76. 10.1158/1541‐7786.MCR‐10‐056810.1158/1541‐7786.MCR‐10‐0568 ↗
77. 10.1158/0008‐5472.CAN‐06‐041010.1158/0008‐5472.CAN‐06‐0410 ↗
78. 10.1007/s12195‐018‐0523‐110.1007/s12195‐018‐0523‐1 ↗
79. 10.1158/0008‐5472.CAN‐03‐347410.1158/0008‐5472.CAN‐03‐3474 ↗
80. Differential Expression of Cell Surface Molecules in Prostate Cancer Cells1
81. 10.1016/j.celrep.2016.04.03510.1016/j.celrep.2016.04.035 ↗
82. 10.1016/j.biopha.2021.11169210.1016/j.biopha.2021.111692 ↗
83. 10.1016/j.lfs.2022.12093610.1016/j.lfs.2022.120936 ↗
84. 10.1002/advs.20241299510.1002/advs.202412995 ↗
85. 10.1021/acsomega.3c0070510.1021/acsomega.3c00705 ↗
86. 10.1016/j.toxicon.2006.09.03010.1016/j.toxicon.2006.09.030 ↗
87. 10.1002/cphy.c15001810.1002/cphy.c150018 ↗
88. 10.1158/1541‐7786.MCR‐16‐016410.1158/1541‐7786.MCR‐16‐0164 ↗
89. 10.1126/science.119327010.1126/science.1193270 ↗
90. 10.3892/ol.2015.352210.3892/ol.2015.3522 ↗
91. 10.1038/nbt.343710.1038/nbt.3437 ↗
92. 10.1038/nmeth.304710.1038/nmeth.3047 ↗
93. 10.1093/nar/gks59610.1093/nar/gks596 ↗
94. 10.1093/nar/gku93610.1093/nar/gku936 ↗
95. 10.1093/nar/gkad96510.1093/nar/gkad965 ↗
96. 10.1093/nar/30.1.20710.1093/nar/30.1.207 ↗